Dipeptidyl peptidase-4 inhibitors are effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher body mass index and insulin resistance

Junji Kozawa1,2*, Tetsuhiro Kitamura1, Hitoshi Nishizawa1, Tetsuyuki Yasuda1, Norikazu Maeda1, Michio Otsuki1, Kohei Okita1, Hiromi Iwahashi1, Hideaki Kaneto1, Tohru Funahashi1,3, Akihisa Imagawa1, Ichiro Shimomura1

ABSTRACT

Aims/Introduction: Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors have become available in Japan. It has not yet been clarified what clinical parameters could discriminate DPP-4 inhibitor-effective patients from DPP-4 inhibitor-ineffective patients.

Materials and Methods: We reviewed 33 consecutive patients with type 2 diabetes admitted to Osaka University Hospital for glycemic control. All of the patients were treated with medical nutrition therapy plus insulin therapy to improve fasting plasma glucose (FPG) and postprandial glucose below 150 and 200 mg/dL, respectively. After insulin secretion and insulin resistance were evaluated, insulin was replaced by DPP-4 inhibitors. The efficacy of DPP-4 inhibitors was determined according to whether glycemic control was maintained at the target levels.

Results: Dipeptidyl peptidase-4 inhibitors were effective in 16 of 33 patients. DPP-4 inhibitor-effective patients were younger than DPP-4 inhibitor-ineffective patients. Body mass index (BMI) was significantly higher in DPP-4 inhibitor-effective patients. Endogeneous insulin-secreting capacity, including insulinogenic index (II), fasting plasma C-peptide (F-CPR) and C-peptide index (CPI), was more sustained in DPP-4 inhibitor-effective patients than DPP-4 inhibitor-ineffective patients. Insulin resistance evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) was significantly higher in DPP-4 inhibitor-effective patients than DPP-4 inhibitor-ineffective patients. In receiver operating characteristic analyses, the cut-off values for predicting the efficacy of DPP-4 inhibitors were 0.07 for II, 1.5 ng/mL for F-CPR, 1.0 for CPI, 23.0 kg/m² for BMI, 1.3 for HOMA-IR and 67.5 years for age.

Conclusions: Dipeptidyl peptidase-4 inhibitors were effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher BMI and insulin resistance. (J Diabetes Invest doi: 10.1111/jdi.12016, 2013)

KEY WORDS: Dipeptidyl peptidase-4 inhibitor, Insulin secretion, Type 2 diabetes

INTRODUCTION

The prevalence of type 2 diabetes has been rapidly increasing worldwide1. According to the National Health and Nutrition Survey in Japan, published in 2008, the number of possible cases of diabetes has also been increasing in Japan; the prevalence was estimated at 13.7 million in 1997, 16.2 million in 2002, 18.7 million in 2006 and 22.1 million in 20072. This is also the case in other Asian countries1,3. It is necessary to develop effective and efficient therapeutic strategies for type 2 diabetes. Recently, incretin-related drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, have become available in Japan. In Caucasian patients with type 2 diabetes, who are in most cases obese or overweight and hyperinsulinemic, DPP-4 inhibitors improve glycemic control with a low risk of hypoglycemia4-6. However, in Japanese or Asian patients with type 2 diabetes, insulin secretion is decreased to varying extents3,7-9. In recent outpatient studies, a DPP-4 inhibitor was more effective in Japanese type 2 diabetic patients with a shorter duration of disease, lower body mass index (BMI) and lower hemoglobin A1c (HbA1c)10-12. However, the characteristics of patients in whom DPP-4 inhibitors are effective, including insulin secretion and insulin resistance, have not yet been clarified in Caucasian, Japanese or other Asian populations. The effectiveness of DPP-4 inhibitor is influenced by each nutrition therapy varying from each other in outpatient study; and characteristics, including insulin secretion and insulin resistance, are easily misjudged by poor glycemic control (glucose toxicity13). Therefore, the characteristics...
of DPP-4 inhibitor-effective patients would be evaluated more clearly only after glycemic control is improved on a regular nutrition therapy.

In this in-patient study, we improved glycemic control by medical nutrition plus insulin therapy and reduced glucose toxicity. We then analyzed the clinical characteristics of patients with type 2 diabetes to detect parameters predicting the efficacy of DPP-4 inhibitors.

**MATERIALS AND METHODS**

**Patients**
We retrospectively reviewed 33 consecutive patients (16 males and 17 females) with type 2 diabetes who were admitted to Osaka University Hospital, Suita, Japan, for glycemic control. The mean (± standard deviation [SD]) age was 68.2 ± 8.2 years, the mean duration of diabetes was 14.1 ± 8.1 years, and the mean BMI was 24.0 ± 3.8 kg/m². The mean HbA₁c level at the time of admission was 9.5 ± 2.7%. Before admission, 25 patients had been treated with oral antidiabetic drugs (OADs), four patients had been treated with OADs plus insulin, three patients had been treated with medical nutrition therapy and one patient had been treated with insulin. OADs included sulfonylurea in 21 patients, biguanide in 11 patients, alpha-glucosidase inhibitor in 10 patients, DPP-4 inhibitor in six patients, thiazolidinedione in five patients and phenylalanine derivative in two patients. Glutamic acid decarboxylase (GAD)-specific antibodies and ketonuria were negative in all patients.

**Protocol**
After admission, all of the patients were treated by medical nutrition therapy plus insulin therapy to improve preprandial plasma glucose, including fasting plasma glucose (FPG) below 150 mg/dL and postprandial plasma glucose below 200 mg/dL. OADs were discontinued, with the exception of biguanide in seven patients. After glycemic control was maintained at the target levels for at least 3 days, insulin secretion and insulin resistance were evaluated. At the time of evaluation, the mean FPG was 128.9 ± 23.0 mg/dL. Insulin therapy was then replaced by DPP-4 inhibitor administration. The administered DPP-4 inhibitors included sitagliptin in 27 patients, vildagliptin in four patients and alogliptin in two patients. The efficacy of the DPP-4 inhibitors was evaluated by examining whether glycemic control was maintained in the hospital at the aforementioned target levels without additional OAD(s) or insulin administration at least for 3 days.

**Evaluation of Insulin Secretion and Insulin Resistance**
Insulin secretion was evaluated using the insulogenic index (II) of a 75 g-oral glucose tolerance test (OGTT), fasting C-peptide (F-CPR) level, C-peptide index (CPI)¹⁴ and homeostasis model assessment of β-cell function (HOMA-β). CPI was calculated by using the following formula: F-CPR (ng/mL) × 100 / FPG (mg/dL). HOMA-β was calculated by using the following formula: fasting immuno reactive insulin (F-IRI; μU/mL) × 360 / (FPG [mg/dL] – 63). Insulin resistance was evaluated with homeostasis model assessment of insulin resistance (HOMA-IR), which was calculated by using the following formula: FPG (mg/dL) × F-IRI (μU/mL) / 405. HOMA-β and HOMA-IR were not evaluated in nine patients treated with intermediate-acting insulin or long-acting insulin, because of the cross-reactivity to exogenous insulin by endogenous fasting insulin concentration, which is necessary for the calculations of HOMA. A total of 12 patients were excluded from the evaluation of II, because they did not undergo 75 g-OGTT randomly. All of these parameters were evaluated after glycemic control had been maintained at the target levels for at least 3 days and before DPP-4 inhibitor therapy was initiated.

**Statistics**
Data are presented as the mean ± SD. A receiver operating characteristic (ROC) curve was used to determine the appropriate clinical parameter cut-off values for identifying patients for whom DPP-4 inhibitor therapy was effective. The Mann–Whitney test was used to compare the clinical characteristics of DPP-4 inhibitor-effective patients and DPP-4 inhibitor-ineffective patients. All statistical analyses were carried out with StatView (Statistical Analysis System Inc., Cary, NC, USA) or the SPSS software package (version 11.0.1J; SPSS, Chicago, IL, USA).

**RESULTS**
DPP-4 inhibitors were effective in 16 of 33 patients. The mean duration of the hospitalization in all the patients was 31.5 ± 10.0 days. There was no significant difference between DPP-4 inhibitor-effective and DPP-4 inhibitor-ineffective patients. The clinical characteristics of the studied patients are shown in Table 1. There were significant differences in age, BMI and the insulin secretion parameters, including II, F-CPR and CPI, between DPP-4 inhibitor-effective and DPP-4 inhibitor-ineffective patients (Table 1). There was also a significant difference in HOMA-IR between these patient groups (Table 1). Therefore, the insulin-secreting capacity and the degree of insulin resistance of DPP-4 inhibitor-effective patients were larger than those of DPP-4 inhibitor-ineffective patients. There was no significant difference in HbA₁c at the time of admission or insulin requirement before DPP-4 inhibitor treatment initiation. Biguanide was used throughout the study to treat four DPP-4 inhibitor-effective patients and three DPP-4 inhibitor-ineffective patients. No other OADs were used during insulin therapy or DPP-4 inhibitor therapy before the evaluation of the efficacy of the DPP-4 inhibitors. The appropriate cut-off values for predicting the efficacy of the DPP-4 inhibitors and the area under the curves (AUCs) in the ROC analyses are shown in Table 2, in addition to the positive and negative predictive values. All parameters, including II, F-CPR, CPI, BMI, HOMA-IR and age, had high AUCs, and all cut-off values showed high positive and negative predictive values. Of these parameters, II had the highest AUC, and its cut-off value
Kozawa et al.

Table 1 | Clinical characteristics of the patients with type 2 diabetes for whom dipeptidyl peptidase-4 inhibitor was effective or ineffective

| Parameters                      | Effective | Ineffective | P-value |
|---------------------------------|-----------|-------------|---------|
| n (Male/female)                 | 16 (8/8)  | 17 (8/9)    | 0.028   |
| Age (years)                     | 64.8 ± 8.5| 71.3 ± 6.8  |         |
| Duration (years)                | 11.6 ± 8.4| 16.4 ± 7.2  | NS      |
| Body mass index (kg/m²)         | 25.3 ± 2.6| 22.7 ± 4.3  | 0.0069  |
| HbA1c‡ (%), National Glycohemoglobin Standardization Program†† | 10.1 ± 3.5 | 8.8 ± 1.5 | NS |
| Fasting plasma glucose‡ (mg/dL) | 126.9 ± 16.8 | 130.9 ± 28.1 | NS |
| Fasting C-peptide‡ (ng/mL)      | 1.9 ± 0.7 (n = 15) | 1.3 ± 0.7 (n = 12) | 0.0038 |
| C-peptide index‡                | 1.5 ± 0.5 (n = 15) | 1.1 ± 0.7 (n = 14) | 0.0055 |
| Insulinogenic index‡            | 0.16 ± 0.15 (n = 9) | 0.08 ± 0.06 (n = 12) | 0.017 |
| HOMA-β‡                        | 47.9 ± 54.9 (n = 10) | 238 ± 23.2 (n = 14) | NS |
| HOMA-IR‡                       | 2.1 ± 2.0 (n = 10) | 1.1 ± 0.8 (n = 14) | 0.035 |
| Insulin dose‡ (unit/kg)         | 0.30 ± 0.18 | 0.33 ± 0.14 | NS |

Data are means ± standard deviation. †On admission. ‡After glycemic control. HbA1c, hemoglobin A1c; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of beta-cell function; NGSP, National Glycohemoglobin Standardization Program.

DISCUSSION

In the present study, we showed that DPP-4 inhibitors are effective for glycemic control in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher BMI and insulin resistance, and younger age. This is the first report on the clinical characteristics of DPP-4 inhibitor-effective patients that evaluated both insulin secretion and insulin resistance. All of the parameters, including II, F-CPR, CPI, BMI, HOMA-IR and age, were thought to be useful parameters for predicting the efficacy of DPP-4 inhibitors. II in OGTT was the most valuable parameter for discriminating DPP-4 inhibitor-effective patients from DPP-4 inhibitor-ineffective patients, based on II having the highest AUC. This finding is consistent with our previous study, which showed that liraglutide, another incretin-related drug, was effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. After II, the AUCs decreased, in order, as follows: F-CPR, CPI, BMI, HOMA-IR and age. All of these parameters are easier to use than II in a clinical setting. Insulin secretion has often deteriorated to varying degrees in Japanese and other Asian patients with type 2 diabetes. In patients with type 2 diabetes, the prevalence of metabolic syndrome-oriented type 2 diabetes, which is characterized by insulin resistance, increases as much as 45.9% in males and 28.0% in females. These findings suggest that insulin secretion insufficiency, insulin resistance or both might be present in Japanese and other Asian patients with type 2 diabetes. The present study showed that both the insulin-secreting capacity and insulin resistance could be predictive markers for the effectiveness of DPP-4 inhibitors. Therefore, an evaluation of the insulin-secreting capacity and insulin resistance is recommended before initiating DPP-4 inhibitor treatment.

One of the possible reasons why these parameters, including BMI and HOMA-IR, were also useful for predicting the efficacy of DPP-4 inhibitors is the correlation between these parameters and insulin secretion parameters in the patients in the present study. BMI was significantly correlated with F-CPR (r = 0.500, P = 0.0035), CPI (r = 0.485, P = 0.0049), II (r = 0.441, P = 0.046) and HOMA-β (r = 0.554, P = 0.0050). HOMA-IR was also significantly correlated with F-CPR (r = 0.663, P = 0.0006), CPI (r = 0.418, P = 0.047) and HOMA-β (r = 0.879, P < 0.0001). It is also possible that DPP-4 inhibitors

Table 2 | Characteristics of cut-off values of the clinical parameters for predicting the efficacy of dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes

| Parameters                      | Optimal cut-off value | AUC | Sensitivity (%) | Specificity (%) | PV(+) (%) | PV(−) (%) |
|---------------------------------|-----------------------|-----|---------------|-----------------|-----------|-----------|
| Insulinogenic index             | 0.07                  | 0.810| 100.0         | 75.0            | 75.0      | 100.0     |
| Fasting C-peptide (ng/mL)       | 1.5                   | 0.800| 73.3          | 82.4            | 78.6      | 77.8      |
| C-peptide index                 | 1.0                   | 0.788| 80.0          | 70.6            | 68.4      | 84.6      |
| Body mass index (kg/m²)         | 23.0                  | 0.776| 87.5          | 70.6            | 73.7      | 85.7      |
| HOMA-IR                         | 1.3                   | 0.757| 70.0          | 85.7            | 77.8      | 80.0      |
| Age (years)                     | 67.5                  | 0.724| 76.5          | 62.5            | 71.4      | 68.4      |

AUC, area under the receiving operator curve; HOMA-IR, homeostasis model assessment of insulin resistance; PV(+) positive predictive value; PV(−), negative predictive value.
might ameliorate insulin resistance in our patients, as reported in a previous study. In recent outpatient studies, higher HbA1c, lower BMI and a shorter duration of diabetes were associated with the efficacy of DPP-4 inhibitors. In the present study, HbA1c tended to be higher and the duration of diabetes tended to be shorter in DPP-4 inhibitor-effective patients than in DPP-4 inhibitor-ineffective patients. These findings are consistent with those of the previous studies. However, BMI was significantly higher in DPP-4 inhibitor-effective patients in the present study. We previously reported that insulin secretion was significantly higher in obese Japanese type 2 diabetic patients than non-obese patients. It is speculated that insulin secretion is the main determinant of the efficacy of DPP-4 inhibitors, and a higher BMI might reflect more sustained insulin secretion, leading to the effectiveness of the DPP-4 inhibitors in our hospitalized patients. By contrast, in outpatients, a higher BMI might partly reflect overeating, leading to the deteriorating efficacy of DPP-4 inhibitors.

Biguanide is reported to increase the secretion of GLP-1. However, even though the patients treated with biguanide were excluded in the present study, the results were almost the same as the previous ones. That is to say, DPP-4 inhibitors were effective in patients with sustained endogenous insulin-secreting capacity, a higher BMI and relative high insulin resistance (P = 0.01 in II, P = 0.0086 in F-CPR, P = 0.01 in CPI, P = 0.029 in BMI, P = 0.064 in HOMA-IR and P = 0.013 in age).

In the present study, the efficacy of DPP-4 inhibitors was evaluated in a relatively short period. This is because the glucose levels in patients with good glycemic control using DPP-4 inhibitors for at least 3 days were maintained at the target levels throughout the remaining hospitalization. In contrast, the glucose levels in patients whose glycemic control was poorly controlled for at least 3 days after switching insulin to DPP-4 inhibitors did not reach the target levels despite the longer use of DPP-4 inhibitors.

A total of 12 patients did not undergo 75 g-OGTT randomly. The number of patients who were evaluated for II was smaller than those of the patients who were evaluated for the other parameters. This was a study limitation.

In conclusion, DPP-4 inhibitors were effective in Japanese type 2 diabetic patients with sustained endogenous insulin-secreting capacity, a higher BMI and insulin resistance, and younger age. Insulin secretion evaluated by II, F-CPR and CPI, BMI and insulin resistance evaluated by HOMA-IR were all useful parameters for predicting the efficacy of DPP-4 inhibitors. Further prospective studies of these patients after discharge would confirm the usefulness of these parameters.

ACKNOWLEDGMENTS
We thank Dr Tomoo Hayakawa, Dr Yoko Kobayashi, Dr Eri Mitsui, Dr Toshiharu Onodera, Dr Yoshiya Hosokawa, Dr Shugo Sasaki, Dr Yuya Fujishima, Dr Kana Inoue, Dr Tomoko Minami, Dr Yukiko Kurashiki, Dr Fumiyo Kubo, Dr Mayumi Tsuji and Dr Susumu Kashine for their clinical help. We do not have any potential conflicts of interest relevant to this article.

REFERENCES
1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782–787.
2. Ministry of Health, Labour and Welfare of Japan. Outline for the Results of the National Health and Nutrition Survey of Japan2007. Available at http://www.nh.go.jp/eiken/english/research/pdf/nhns2007.pdf (last accessed on 2012, May 9).
3. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129–2140.
4.Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632–2637.
5. Bosi E, Carnisasa RC, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890–895.
6. DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor al biglipitin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315–2317.
7. Qian L, Xu L, Wang X, et al. Early insulin secretion failure leads to diabetes in Chinese subjects with impaired glucose regulation. Diabetes Metab Res Rev 2009; 25: 144–149.
8. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004; 53: 831–835.
9. Toyoda K, Fukushima M, Mitsui R, et al. Factors responsible for age-related elevation in fasting plasma glucose: a cross-sectional study in Japanese men. Metabolism 2008; 57: 299–303.
10. Maeda T, Kubota A, Tanaka Y, et al. The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e20–e22.
11. Nomiyama T, Akehi Y, Takenoshita H, et al. Contributing factors related to efficacy of the dipeptidyl peptidase-4 inhibitor sitagliptin in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2012; 95: e27–e28.
12. Bando Y, Kanekura H, Aoki K, et al. Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients. J Diabetes Invest 2012; 3: 170–174.
13. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13: 610–630.
14. Asano T, Kawamura M, Watanabe T, et al. Indices of urinary and serum C-peptide corrected with fasting plasma glucose for decision-making of insulin therapy in type 2 diabetes-validation and comparison. *Jpn Diabetes Soc* 2008; 51: 759–763 (Japanese).

15. Kozawa J, Inoue K, Iwamoto R, et al. Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity. *J Diabetes Invest* 2012; 3: 294–297.

16. Funahashi T, Matsuzawa Y. Metabolic syndrome: clinical concept and molecular basis. *Ann Med* 2007; 39: 482–494.

17. Shimajiri Y, Tsunoda K, Furuta M, et al. Prevalence of metabolic syndrome in Japanese type 2 diabetic patients and its significance for chronic vascular complications. *Diabetes Res Clin Pract* 2008; 79: 310–317.

18. Kikuchi M, Abe N, Kato M, et al. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2009; 83: 233–240.

19. Kozawa J, Okita K, Imagawa A, et al. Similar incretin secretion in obese and non-obese Japanese subjects with type 2 diabetes. *Biochem Biophys Res Commun* 2010; 393: 410–413.

20. Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. *Diabetologia* 2011; 54: 219–222.